Previous Close | 0.7200 |
Open | 0.7500 |
Bid | 0.7000 x N/A |
Ask | 0.7200 x N/A |
Day's Range | 0.7000 - 0.7500 |
52 Week Range | 0.6000 - 1.0600 |
Volume | |
Avg. Volume | 10,551 |
Market Cap | 31.847M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings Date | Apr 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and that have the potential to treat unmet pediatric diseases, today announced that the European Medicines Agency ("EMA") has accepted its Clinical Trial Application ("CTA") Part I - Scientific and Medicinal Product Documentation, for its lead compound TTI-